# Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis

> **NCT05070221** · PHASE1 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma Stage IV

## Interventions

- **DRUG:** Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)
- **DRUG:** Recombinant humanized anti-PD-1 monoclonal antibody for injection
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT05070221
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05070221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05070221, "Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05070221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*